Meredith A.Stewart

Associate

San Diego + 1.858.314.1155

Meredith Stewart represents biotechnology and pharmaceutical clients in patent disputes. She has practiced in contested cases in federal district court and at the Patent Trial and Appeal Board (PTAB).

Meredith has experience through the life cycle of patent cases, including pre-suit investigation, pleadings, and fact and expert discovery. She has drafted various briefs and motions, including claim construction and case dispositive briefs. Meredith also has worked extensively with expert witnesses, including drafting expert reports.

Before joining Jones Day, Meredith served as a law clerk to Judge Todd M. Hughes of the United States Court of Appeals for the Federal Circuit and as a judicial intern for Judge Cheri Beasley, former Chief Justice of the Supreme Court of North Carolina.

During law school, Meredith received the Faculty Award for Intellectual Property and Technology and was a Margolis Scholar at the Duke-Margolis Center for Health Policy. She also conducted an independent study on the U.S. Food & Drug Administration's evolving regulation of artificial intelligence (AI) medical devices.

Prior to practicing law, Meredith earned her master of public health at the University of North Carolina at Chapel Hill and worked in health care for several years.

Expérience

  • Pharmaceutical company wins $107.5 million jury verdict in patent dispute involving AstraZeneca's lung cancer treatment Tagrisso®Jones Day on behalf of a pharmaceutical company won a jury award of $107.5 million in damages after a five-day trial and less than three hours of jury deliberation.
  • Puma Biotechnology asserts patent infringement claims under Hatch-Waxman Act related to Nerlynx® against SandozJones Day is representing Puma Biotechnology, Inc. in a Hatch-Waxman patent infringement action against Sandoz relating to Sandoz's submission of an Abbreviated New Drug Application to the FDA seeking approval of a purported generic version of Nerlynx® (neratinib) tablets.
  • ToolGen faces off in two patent interferences involving CRISPR/Cas9 applicationJones Day is representing ToolGen, Inc. in two patent interferences involving CRISPR/Cas9 technology.